Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as cangrelor P2Y12 (platelet) inhibitor
cangrelor P2Y12 inhibitor · 1 trial · 3 indications
Clinical Events Committee (CEC)-adjudicated results (modified intent-to-treat \[mITT\] population)
| Arm | Type | Description |
|---|---|---|
| cangrelor | EXPERIMENTAL | Cangrelor was administered as a 30 µg/kg bolus followed by a 4.0 µg/kg/min cangrelor IV infusion for a minimum of 2 hours or until conclusion of the index procedure, whichever is longer. At the discretion of the treating physician, the infusion could be continued for a total duration of 4 hours. Following the discontinuation of the cangrelor infusion, 600mg of clopidogrel was administered. |
| clopidogrel | ACTIVE_COMPARATOR | Clopidogrel 300 mg or 600 mg administered pre or post PCI. Selection of dose and timing of dose were per investigator discretion. During the PCI a placebo infusion was given to maintain the blinding of the trial. In addition, placebo capsules were administered at the end of the infusion mimic the 600mg post infusion dose provided in the cangrelor arm. |
| Name | Type | Description |
|---|---|---|
| cangrelor P2Y12 (platelet) inhibitor | DRUG | - |
| Clopidogrel - 300 or 600 mg (study arm) | DRUG | Over encapsulated tablets. |
| Clopidogrel 600 mg post cangrelor | DRUG | over-encapsulated clopidogrel (600 mg) |
Inclusion Criteria: Patients may be included in the study if they meet all of the following criteria: * Male or non-pregnant female at least 18 years of age * Patients undergoing percutaneous coronary intervention (PCI): 1. Stable angina (SA) patients with diagnostic coronary angiography within...
Top 10 of 16 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 7 | PHASE3 | Ziltivekimab, Zenagamtide |
| Eli Lilly and Company | LLY | 6 | PHASE3 | Lepodisiran, Retatrutide, Muvalaplin, Orforglipron, Clazakizumab |
| Novartis AG Sponsored ADR | NVS | 8 | PHASE3 | Inclisiran, Pelacarsen |
| Amgen Inc. | AMGN | 4 | PHASE3 | Olpasiran, Maridebart cafraglutide |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Enlicitide |
| NewAmsterdam Pharma Company N.V. | NAMS | 2 | PHASE3 | Obicetrapib |
| United Therapeutics Corporation | UTHR | 1 | PHASE3 | Ralinepag |
| Roivant Sciences Ltd. | ROIV | 3 | PHASE3 | Mosliciguat |
| Genentech, Inc. | RHHBY | 1 | PHASE2 | Selnoflast |
| Verve Therapeutics, Inc. | VERV | 2 | PHASE2 | VERVE-102 |
Cangrelor P2Y12 inhibitor is an investigational small molecule being studied in atherosclerosis, including patients undergoing percutaneous coronary intervention and those with acute coronary syndrome. It is a cardiovascular therapy developed by Novartis AG and is currently in Phase 3 clinical development.
Cangrelor P2Y12 inhibitor targets P2RY12, also known as the P2Y12 platelet receptor. It acts as an antagonist at this receptor, which is the target class for this small molecule. By blocking P2RY12, it is designed to inhibit platelet activation in cardiovascular settings.
Cangrelor P2Y12 inhibitor is being developed by Novartis AG, which trades under the ticker NVS. Novartis is the sponsor of the clinical program for this small molecule in cardiovascular indications.
Cangrelor P2Y12 inhibitor is in Phase 3 clinical development. It is an investigational agent and has not been approved by the FDA. The program includes one completed Phase 3 trial, with no active trials currently listed.
Cangrelor P2Y12 inhibitor has been studied in the completed Phase 3 CHAMPION PHOENIX trial, registered as NCT01156571. That trial compared cangrelor to clopidogrel standard therapy in subjects requiring percutaneous coronary intervention, enrolled 11,145 participants, and was randomized, double-blind, and active-controlled.
Yes, cangrelor P2Y12 inhibitor is also known as cangrelor P2Y12 (platelet) inhibitor. Both names refer to the same investigational small molecule developed by Novartis AG that targets the P2RY12 platelet receptor.